Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypoxia as a driver of resistance to immunotherapy.
Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Kopecka J, et al. Among authors: saponara s. Drug Resist Updat. 2021 Dec;59:100787. doi: 10.1016/j.drup.2021.100787. Epub 2021 Nov 18. Drug Resist Updat. 2021. PMID: 34840068 Free article. Review.
The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. Assaraf YG, et al. Among authors: saponara s. Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17. Drug Resist Updat. 2019. PMID: 31585396 Review.
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
Gazzano E, Rolando B, Chegaev K, Salaroglio IC, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C. Gazzano E, et al. Among authors: saponara s. J Control Release. 2018 Jan 28;270:37-52. doi: 10.1016/j.jconrel.2017.11.042. Epub 2017 Dec 2. J Control Release. 2018. PMID: 29191785 Free article.
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, Saponara S, Sorge M, Hattinger CM, Gasco A, Fruttero R, Brancaccio M, Serra M, Stella B, Fattal E, Arpicco S, Riganti C. Gazzano E, et al. Among authors: saponara s. Cancer Lett. 2019 Aug 1;456:29-39. doi: 10.1016/j.canlet.2019.04.029. Epub 2019 Apr 29. Cancer Lett. 2019. PMID: 31047947 Free article.
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.
Bigagli E, Luceri C, De Angioletti M, Chegaev K, D'Ambrosio M, Riganti C, Gazzano E, Saponara S, Longini M, Luceri F, Cinci L. Bigagli E, et al. Among authors: saponara s. Invest New Drugs. 2018 Dec;36(6):985-998. doi: 10.1007/s10637-018-0590-0. Epub 2018 Apr 2. Invest New Drugs. 2018. PMID: 29607467
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.
Alov P, Al Sharif M, Aluani D, Chegaev K, Dinic J, Divac Rankov A, Fernandes MX, Fusi F, García-Sosa AT, Juvonen R, Kondeva-Burdina M, Padrón JM, Pajeva I, Pencheva T, Puerta A, Raunio H, Riganti C, Tsakovska I, Tzankova V, Yordanov Y, Saponara S. Alov P, et al. Among authors: saponara s. Front Pharmacol. 2022 Mar 7;13:831791. doi: 10.3389/fphar.2022.831791. eCollection 2022. Front Pharmacol. 2022. PMID: 35321325 Free PMC article.
Repurposing old drugs to fight multidrug resistant cancers.
Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Dinić J, et al. Among authors: saponara s. Drug Resist Updat. 2020 Sep;52:100713. doi: 10.1016/j.drup.2020.100713. Epub 2020 Jun 25. Drug Resist Updat. 2020. PMID: 32615525 Review.
101 results